Recurrent Vulvovaginal Candidiasis Rvvc — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for recurrent vulvovaginal candidiasis rvvc . 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
5
Active US patents
38/100
Avg vulnerability
—
Annual revenue covered

Originators in Recurrent Vulvovaginal Candidiasis Rvvc

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Mycovia Pharms 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating recurrent vulvovaginal candidiasis rvvc . Each bar = one year. Y-axis scaled to peak year (2 patents).

2
31
1
33
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vivjoa
OTESECONAZOLE
 Mycovia Pharms 5 38 — 2031-04-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8754227 Vivjoa method of use 76 2031-04-22
11247981 Vivjoa method of use 70 2033-05-09
8236962 Vivjoa composition of matter 18 2031-04-22
10414751 Vivjoa composition of matter 12 2036-03-17
9840492 Vivjoa composition of matter 12 2036-03-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10414751 Vivjoa composition of matter 12 2036-03-17
9840492 Vivjoa composition of matter 12 2036-03-17
8236962 Vivjoa composition of matter 18 2031-04-22
11247981 Vivjoa method of use 70 2033-05-09
8754227 Vivjoa method of use 76 2031-04-22

Related